EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Experiences from Two Decades of HTLV-1/2 Testing in a Low-Prevalence Area in Southern Germany, 2004 to 2024

Klaus Korn iD, Philipp Steininger iD, Barbara Schmidt iD, Andrea K Thoma-Kress iD, Lennart Forneck, Antje Knöll iD

Viruses · 12.08.2026 · 18 (8) · 882

DOI: 10.3390/v18080882 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 12.08.2026. Verfasst von Klaus Korn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Harald zur Hausen Institute of Virology, University Hospital Erlangen, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Schlossgarten 4, 91054 Erl…. Hauptthemen laut MEDLINE: Human T-lymphotropic virus 1, Human T-lymphotropic virus 2, HTLV-I Infections, HTLV-II Infections. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human T-cell lymphotropic virus type 1 (HTLV-1) is a neglected pathogen with a heterogeneous global distribution. In low-prevalence areas, diagnostic testing is challenged by limited clinical awareness and the low positive predictive value of screening tests. We retrospectively analyzed 10,891 HTLV-1/2 test results from 7719 patient samples submitted to a specialized laboratory in Germany between 2004 and 2024. Antibody screening had a positive predictive value (PPV) of 31.7% for the Diasorin Murex HTLV I + II assay (39 of 123 reactive samples confirmed) and 34.5% for the Abbott Architect rHTLV-1/2 assay (67 of 194 reactive samples confirmed). Raising the sample/cutoff (s/co) threshold to ≥5 would have increased the PPV to >80%, with only two missed diagnoses per assay. HTLV-1 infection was confirmed in 124 carriers and HTLV-2 infection in three carriers. The vast majority of carriers originated from countries with higher endemicity. A delayed antibody response was observed in HTLV-1 infections via organ transplantation. In four patients with neurological disease, elevated HTLV-1/2-specific antibody indices showed antibody production in cerebrospinal fluid (CSF). HTLV-1 proviral load was measured in 83 carriers, with a median of 20,000 HTLV-1 DNA copies per 106 cells (interquartile range, 4000–119,600). Seventy-four percent (17/23) of high-dose intravenous immunoglobulin (IVIg) preparations contained HTLV-1/2 antibodies, which can lead to false-positive HTLV-1/2 antibody screening results in recipients without underlying infection. Therefore, HTLV-1/2 testing presents two major pitfalls: false-negative results in immunosuppressed patients and false-positive results following IVIg administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human T-lymphotropic virus 1Human T-lymphotropic virus 2HTLV-I InfectionsHTLV-II InfectionsHumansGermanyRetrospective StudiesFemalePrevalenceMaleMiddle AgedAdultAgedPredictive Value of TestsAntibodies, Viral

Stichwörter der Autor:innen

GermanyHTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)adult T-cell leukemia/lymphoma (ATL)antibody detectiondiagnosticshuman T-cell lymphotropic virus type 1 (HTLV-1)human T-cell lymphotropic virus type 2 (HTLV-2)proviral load

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Harald zur Hausen Institute of Virology, University Hospital Erlangen, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany.
  • Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

ORCID-Profile: Klaus Korn, Philipp Steininger, Barbara Schmidt, Andrea K Thoma-Kress, Antje Knöll

Zitieren

APA

Korn, K., Steininger, P., Schmidt, B., Thoma-Kress, A. K., Forneck, L., & Knöll, A. (2026). Experiences from Two Decades of HTLV-1/2 Testing in a Low-Prevalence Area in Southern Germany, 2004 to 2024. Viruses, 18(8), 882. https://doi.org/10.3390/v18080882

Vancouver

Korn K, Steininger P, Schmidt B, Thoma-Kress AK, Forneck L, Knöll A. Experiences from Two Decades of HTLV-1/2 Testing in a Low-Prevalence Area in Southern Germany, 2004 to 2024. Viruses. 2026;18(8):882. doi:10.3390/v18080882

BibTeX
@article{Korn2026,
  author = {Korn, Klaus and Steininger, Philipp and Schmidt, Barbara and Thoma-Kress, Andrea K and Forneck, Lennart and Knöll, Antje},
  title = {Experiences from Two Decades of HTLV-1/2 Testing in a Low-Prevalence Area in Southern Germany, 2004 to 2024},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {882},
  doi = {10.3390/v18080882}
}
Kostenlos starten →